Ocular Therapeutix (OCUL) Stock Forecast: What Could Drive It in 2026
Short answer
What is actually driving Ocular Therapeutix (OCUL) right now is AXPAXLI in wet AMD: The lead asset is a sustained-release axitinib implant aimed at reducing the frequent anti-VEGF injections wet-AMD patients currently need. Revenue (FY2025) is ~$52 million. If that keeps playing out, the setup is favourable; the risk to it is the stock is a high-risk, single-asset biotech: most of its value depends on AXPAXLI clearing remaining trials, winning FDA approval, and then being adopted by retina specialists who are comfortable with established anti-VEGF drugs. No one can predict where OCUL trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Ocular Therapeutix (OCUL) higher?
1. AXPAXLI in wet AMD.
The lead asset is a sustained-release axitinib implant aimed at reducing the frequent anti-VEGF injections wet-AMD patients currently need. In the Phase 3 SOL-1 trial it met a superiority primary endpoint versus aflibercept (p=0.0006), with a larger share of patients maintaining vision. A durability and label advantage over standard care is the central driver of the company's value.
2. Expanding Phase 3 pipeline.
Beyond SOL-1, Ocular is running the SOL-R registrational trial and the HELIOS-3 study, and it has advanced programs in non-proliferative diabetic retinopathy. Success across multiple retinal indications would broaden AXPAXLI's addressable market well past wet AMD, though each trial adds cost and its own binary risk.
3. Approved product plus hydrogel platform.
DEXTENZA provides real, if modest, commercial revenue (around $52 million in 2025) and a fielded sales infrastructure. The underlying bioresorbable hydrogel delivery platform is reusable across drugs and diseases, giving the company a technology base that could support additional products over time.
4. Well-funded balance sheet.
Cash of about $666.7 million as of March 31, 2026, is expected to fund operations, including multiple Phase 3 programs, into 2028. That runway lets Ocular pursue AXPAXLI approval without immediate financing pressure, although continued heavy R&D spending steadily consumes the balance.
What could weigh on OCUL?
The stock is a high-risk, single-asset biotech: most of its value depends on AXPAXLI clearing remaining trials, winning FDA approval, and then being adopted by retina specialists who are comfortable with established anti-VEGF drugs. Wet AMD is intensely competitive, with entrenched blockbusters like Regeneron's Eylea and Roche's Vabysmo plus other long-acting and gene-therapy approaches in development. The company is deeply unprofitable, posting a net loss of about $88.6 million in the first quarter of 2026 as R&D climbed, and it may need additional capital that could dilute shareholders. Regulatory setbacks, trial delays, safety findings, or slower-than-hoped commercial uptake could each move the shares sharply lower, and DEXTENZA revenue is too small to cushion a pipeline disappointment.
Where OCUL trades today
A forecast starts from where the stock actually is. These are OCUL's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for OCUL as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a OCUL forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the OCUL guide and whether OCUL is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the OCUL outlook
The bottom line: what is driving Ocular Therapeutix (OCUL) is AXPAXLI in wet AMD, with revenue (fy2025) at ~$52 million. If that keeps playing out the setup is favourable; the risk is the stock is a high-risk, single-asset biotech: most of its value depends on AXPAXLI clearing remaining trials, winning FDA approval, and then being adopted by retina specialists who are comfortable with established anti-VEGF drugs. No one can predict the price, so treat any OCUL forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around OCUL with Walnut
Use Ocular Therapeutix as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Ocular Therapeutix (OCUL)?
+
No one can reliably predict where OCUL will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Ocular Therapeutix higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive OCUL higher?
+
The main growth drivers are AXPAXLI in wet AMD; Expanding Phase 3 pipeline; Approved product plus hydrogel platform. Whether they play out is the real question, not a guaranteed path.
What are the risks to OCUL?
+
The stock is a high-risk, single-asset biotech: most of its value depends on AXPAXLI clearing remaining trials, winning FDA approval, and then being adopted by retina specialists who are comfortable with established anti-VEGF drugs. Wet AMD is intensely competitive, with entrenched blockbusters like Regeneron's Eylea and Roche's Vabysmo plus other long-acting and gene-therapy approaches in development. The company is deeply unprofitable, posting a net loss of about $88.6 million in the first quarter of 2026 as R&D climbed, and it may need additional capital that could dilute shareholders. Regulatory setbacks, trial delays, safety findings, or slower-than-hoped commercial uptake could each move the shares sharply lower, and DEXTENZA revenue is too small to cushion a pipeline disappointment.
Will OCUL stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Ocular Therapeutix's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is OCUL a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the OCUL "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.